Merck’s Sotatercept Hits Phase III Marks In Mid-Stage PAH Patients

The pharma’s pulmonary arterial hypertension candidate, touted as a future blockbuster seller, showed benefit on six-minute walk distance and several secondary endpoints in Phase III STELLAR.